Dimerix Limited (ASX: DXB) - Share Price

- Current share price for DXB : $0.250

Dimerix Limited (DXB) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a clinical-stage biopharmaceutical company focused on improving the lives of patients with inflammatory diseases, including kidney disease. The company is developing its proprietary Phase 3 product candidate DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and DMX-700 for orphan respiratory / renal Disease. Both DMX-200 and DMX-700 were identified using Dimerix's proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), a scalable and globally applicable technology platform that enables the understanding of receptor interactions to rapidly screen and identify new drug opportunities.

DXB General Information ⁺

ASX Code	DXB
Website	N/A
Industry/Sector	Biotechnology
Market Cap ($M)	150
DXB Share Price	$0.250
Day High	$0.255
Day Low	$0.245
Last Close	$0.250
DXB Share Price Movement	- ( No change )

Prices as at 16:40, 11 Sep 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Dimerix Limited (DXB) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Dimerix Limited (DXB) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Dimerix Limited (DXB) price-sensitive announcements

DXB - Dimerix Receives US$10M Upfront Payment from Everest

Dimerix Limited, an Australian clinical-stage biopharmaceutical company focusing on kidney

Dimerix Limited (DXB)
20 Aug 2026 | 9:13 AM

DXB - Dimerix Assumes Sponsorship of US IND for New Asset DMX-652

Dimerix Limited announced it has assumed sponsorship of the U.S. Investigational New Drug

Dimerix Limited (DXB)
17 Aug 2026 | 8:38 AM

DXB - Dimerix Presents at Bioshares Summit 2026

Dimerix Limited, an Australian clinical-stage biopharmaceutical company, presented its str

Dimerix Limited (DXB)
6 Aug 2026 | 8:17 AM

DXB - Dimerix Quarterly Activities Report and Appendix 4C

Dimerix Limited, a biopharmaceutical company, announced its quarterly activities report fo

Dimerix Limited (DXB)
30 Jul 2026 | 8:49 AM

Dimerix Limited (DXB) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Dimerix Limited (DXB) ORDINARY FULLY PAID	Health Care	$150	Dimerix Investor Presentation	7 Sep 2026 8:51AM	$0.285	$0.250	fallen by 12.28%
Dimerix Limited (DXB) ORDINARY FULLY PAID	Health Care	$150	S&P DJI Announces September 2026 Quarterly Rebalance	4 Sep 2026 5:10PM	$0.285	$0.250	fallen by 12.28%
Dimerix Limited (DXB) ORDINARY FULLY PAID	Health Care	$150	Dimerix Secures A$34 Million Non-Dilutive Funding Facility	4 Sep 2026 9:17AM	$0.290	$0.250	fallen by 13.79%
Dimerix Limited (DXB) ORDINARY FULLY PAID	Health Care	$150	Trading Halt	2 Sep 2026 8:43AM	$0.290	$0.250	fallen by 13.79%
Dimerix Limited (DXB) ORDINARY FULLY PAID	Health Care	$150	Appendix 4G and Corporate Governance Statement	27 Aug 2026 8:56AM	$0.290	$0.250	fallen by 13.79%
Dimerix Limited (DXB) ORDINARY FULLY PAID	Health Care	$150	Appendix 4E and 2026 Annual Report	27 Aug 2026 8:56AM	$0.290	$0.250	fallen by 13.79%

DXB Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2026A	-$29.81	-$5.00	110.60%	0.00%	0.0%
2025A	-$13.25	-$2.40	-37.40%	0.00%	0.0%
2024A	-$17.08	-$3.80	-11.10%	0.00%	0.0%

DXB Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A
CSL Limited (CSL)	$81,340M	0.7309	-0.4434	0.0546	10.5009	18.8662	17.8903	2.51%	2.46%	2.54%
Clinuvel Pharmaceuticals Limited (CUV)	$404M	-0.0696	-0.0719	0.0242	11.9910	12.9194	12.6142	0.62%	0.62%	0.62%
Dimerix Limited (DXB)	$150M	1.1059	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Mesoblast Limited (MSB)	$2,818M	-0.4380	0.0000	0.0000	0.0000	0.0000	344.4444	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$5,695M	-1.3893	0.0000	-0.9100	0.0000	160.3828	1,782.9787	0.00%	0.00%	0.00%

DXB Directors

Name	Position	Start Date
Dr Nina Webster	Chief Executive Officer, Managing Director	27 Aug 2018
Mr Mark P Diamond	Non-Executive Chairman, Non-Executive Director	1 Dec 2023
Mr Hugh Alsop	Non-Executive Director	1 May 2017
Dr Sonia Maria Poli	Non-Executive Director	3 Jul 2015
Mr Clinton Snow	Non-Executive Director	1 May 2023

Dimerix Limited (DXB) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
12 Dec 2025	SNOW, Clinton	Issued	Options	300,000	$0.321	$96,300.000
12 Dec 2025	ALSOP, Hugh	Issued	Options	300,000	$0.321	$96,300.000
12 Dec 2025	WEBSTER, Nina	Issued	Options	2,500,000	$0.437	$1,093,500.000

See all changes in directors' interest & trades for Dimerix Limited (DXB) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

DXB Management

Name	Position
Dr Robert Shepherd	Chief Commercialisation Officer
Michael (Mike) Tonroe	Chief Financial Officer,Company Secretary
Dr David Fuller	Chief Medical Officer

DXB Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Dimerix Limited (DXB). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
40,018,964 (6.67%)	Mr Peter Meurs
36,865,281 (6.14%)	Skiptan Pty Ltd ATFT P&M Meurs Family Trust

DXB Calendar of Events

Date	Event
26 August 2027	Report (Annual)
26 August 2027	Report (Prelim)
25 February 2027	Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us